BridgeBio Oncology Therapeutics, Inc. financial data

Symbol
BBOT on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1210% % 45%
Debt-to-equity 21% %
Return On Equity -125% % -356%
Return On Assets -40% % 0.12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80,032,823 shares
Common Stock, Shares, Outstanding 79,991,768 shares 281412%
Entity Public Float $465,152,172 USD 184%
Common Stock, Value, Issued $8,000 USD
Weighted Average Number of Shares Outstanding, Basic 79,987,399 shares 337%
Weighted Average Number of Shares Outstanding, Diluted 79,987,399 shares 337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $38,074,000 USD 95%
General and Administrative Expense $23,006,034 USD 431%
Operating Income (Loss) $96,132,034 USD -130%
Nonoperating Income (Expense) $13,008,952 USD 61%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $134,044,000 USD -80%
Earnings Per Share, Basic -490 USD/shares 54%
Earnings Per Share, Diluted -490 USD/shares 54%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $373,687,000 USD 1111%
Marketable Securities, Current $51,773,000 USD -59%
Cash, Cash Equivalents, and Short-term Investments $425,500,000 USD
Assets, Current $432,396,000 USD 172%
Property, Plant and Equipment, Net $956,000 USD 95%
Operating Lease, Right-of-Use Asset $2,330,000 USD
Other Assets, Noncurrent $12,567,000 USD 152%
Assets $448,381,000 USD 173%
Accounts Payable, Current $1,374,000 USD -55%
Accrued Liabilities, Current $1,783,561 USD 7544%
Liabilities, Current $35,041,000 USD 79%
Operating Lease, Liability, Noncurrent $2,244,000 USD
Liabilities $37,285,000 USD 90%
Accumulated Other Comprehensive Income (Loss), Net of Tax $16,000 USD -95%
Retained Earnings (Accumulated Deficit) $356,567,000 USD -60%
Stockholders' Equity Attributable to Parent $411,096,000 USD
Liabilities and Equity $448,381,000 USD 173%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $734,642 USD -19%
Common Stock, Shares Authorized 500,000,000 shares 1109%
Common Stock, Shares, Issued 79,991,768 shares 281412%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $373,819,000 USD 1107%
Deferred Tax Assets, Valuation Allowance $87,182,000 USD 93%
Deferred Tax Assets, Gross $87,882,000 USD 1845%
Operating Lease, Liability $2,766,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $44,772,000 USD -171%
Lessee, Operating Lease, Liability, to be Paid $3,235,000 USD
Operating Lease, Liability, Current $522,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $730,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $705,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.074 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $469,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $755,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $42,732,000 USD 212%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $2,164,000 USD 65%
Lessee, Operating Lease, Liability, to be Paid, Year Four $782,000 USD
Additional Paid in Capital $767,639,000 USD 1663%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $700,000 USD 6264%
Share-based Payment Arrangement, Expense $1,425,000 USD 86%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%